Radiofrequency ablation of renal tumors: four-year follow-up results in 47 patients

To retrospectively evaluate the intermediate results of radiofrequency ablation (RFA) of small renal masses (SRMs). Percutaneous or laparoscopic RFA was performed on 48 renal tumors in 47 patients. The follow-up studies included a physical examination, chest radiography, creatinine level, and contra...

Full description

Saved in:
Bibliographic Details
Published in:Korean journal of radiology 2012, 13(5), , pp.625-633
Main Authors: Kim, Soo Dong, Yoon, Seong Guk, Sung, Gyung Tak
Format: Article
Language:English
Subjects:
Ablation
Adult
Aged
Biopsy
Catheter Ablation - methods
Contrast Media
Female
Follow-Up Studies
Humans
Kidney cancer
Kidney Neoplasms - surgery
Laparoscopy
Magnetic Resonance Imaging
Male
Medical imaging
Middle Aged
Neoplasm Recurrence, Local
Original
Patients
Postoperative Complications
Radiography, Thoracic
Reoperation
Retrospective Studies
Success
Tomography, X-Ray Computed
Treatment Outcome
Tumors
Ultrasonic imaging
방사선과학
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:To retrospectively evaluate the intermediate results of radiofrequency ablation (RFA) of small renal masses (SRMs). Percutaneous or laparoscopic RFA was performed on 48 renal tumors in 47 patients. The follow-up studies included a physical examination, chest radiography, creatinine level, and contrast-enhanced CT or MRI. To confirm the pathologic criteria of complete ablation, 35 patients underwent a follow-up biopsy. Recurrence was defined as contrast enhancement on imaging studies after 3 months, lesion growth at subsequent imaging, or viable cancer cells on follow-up biopsy. Technical success was achieved in 43 (89.6%) of 48 renal tumors. The mean tumor size was 2.3 cm and the mean follow-up period was 49.6 months. Repeated RFA was necessary in 5 tumors due to incomplete ablation. The overall complication rate was 35.8%, of which 96.2% were mild complications. Serum creatinine levels at 12 months after RFA did not differ from those before RFA (1.28 vs. 1.36 mg/dL). Four patients were found to have recurrence at various follow-up intervals, and distant metastasis was not found in any cases. RFA appears to be a useful treatment for selected patients with SRMs. Our 4-year follow-up results disclose an excellent therapeutic outcome with RFA, while achieving effective local tumor control.
ISSN:1229-6929
2005-8330
DOI:10.3348/kjr.2012.13.5.625